Cochlear implants are associated with reduced cognitive decline risk: A 20‐year cohort study Authors: Filippos Anagnostakis, Michail Kokkorakis, Ilias Papadimopoulos, Junhao Wen, Christos Davatzikos Published: 2026 ABSTRACT AbstractIntroductionWe investigated the association between cochlear implantation and the risk of cognitive decline in adults with hearing loss using a national population cohort.MethodsOur cohort comprised 4106 participants who underwent cochlear implantation and matched controls with untreated hearing loss, followed over a median of 7.3 years. Propensity score matching was applied to control for confounders, and Kaplan–Meier analysis was used to assess time‐to‐event outcomes.ResultsParticipants with cochlear implants had a significantly reduced risk of all‐cause dementia (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.50–0.74), mild cognitive impairment (HR 0.53, 95% CI 0.40–0.70), and memory loss (HR 0.54, 95% CI 0.45–0.65) compared with controls. These associations remained significant in sex‐stratified analyses for both male and female participants.DiscussionThese results support early auditory intervention as a dementia prevention strategy and warrant further research with longer follow‐up periods across diverse populations.Keywords: cochlear implants, dementia, epidemiology, hearing loss, MCI, memory loss INTRODUCTION As the population ages, the global burden of dementia continues to rise. In 2019, more than 57 million people worldwide were living with dementia, a number projected to nearly triple by 2050. 1 Among the risk factors for dementia, hearing loss has emerged as one of the leading modifiable risk factors for dementia, with hearing impairment in midlife contributing substantially to later‐life cognitive decline. 2 Previous work has indicated that untreated hearing loss is associated with an accelerated trajectory of cognitive decline, 2 highlighting the potential for early auditory interventions as a preventive strategy. The 2024 Lancet Commission on Dementia estimated that addressing hearing loss could prevent up to 7% of dementia cases globally, representing the most important modifiable risk factor identified to date. 2 At the same time, a growing body of evidence suggests that hearing aids may improve cognitive performance and reduce dementia risk. 3 , 4 , 5 In addition, a recent systematic review and meta‐analysis (31 studies; n = 137,484) reported that cochlear implant recipients showed small but consistent short‐term gains in general cognition (7 studies; n = 351; pooled ratio of means 1.03, 95% confidence interval [CI] 1.02–1.05; follow‐up 3‐12 months), although the overall certainty of evidence was graded as low and the impact of cochlear implants on dementia remains unclear. 3 In this large national cohort of adults with hearing loss with up to two decades of follow‐up, we aimed to investigate whether cochlear implantation is associated with a reduced risk of all‐cause dementia, mild cognitive impairment, and memory loss. METHODS Data sources The study was conducted using data from the US Collaborative Network of the TriNetX Analytics platform, which consists of de‐identified electronic health record (EHR) data. Informed consent was waived because the study used de‐identified secondary data. RESEARCH IN CONTEXT Systematic Review: The authors searched PubMed and reviewed references from relevant articles. Although substantial evidence links hearing loss to dementia, the impact of cochlear implantation on cognitive decline remains unclear. Systematic Review: The authors searched PubMed and reviewed references from relevant articles. Although substantial evidence links hearing loss to dementia, the impact of cochlear implantation on cognitive decline remains unclear. Interpretation: In this 20‐year cohort study (median follow‐up: 7.3 years), participants who underwent cochlear implantation showed a significantly lower risk of memory loss, mild cognitive impairment, and dementia compared to matched controls. Interpretation: In this 20‐year cohort study (median follow‐up: 7.3 years), participants who underwent cochlear implantation showed a significantly lower risk of memory loss, mild cognitive impairment, and dementia compared to matched controls. Future Directions: Large‐scale trials should evaluate cochlear implants as a viable dementia prevention strategy for individuals with severe hearing loss. Future Directions: Large‐scale trials should evaluate cochlear implants as a viable dementia prevention strategy for individuals with severe hearing loss. Study design We identified patients with hearing loss older than 50 years of age. Participants who underwent cochlear implantation were compared with control participants with hearing loss who did not undergo the procedure between April 1, 2005, and December 31, 2018 (Figure 1). Details on inclusion and exclusion criteria, along with their corresponding diagnostic codes, are provided in Tables S1–S3. Flowchart. Baseline data were derived from participants’ EHR records from April 1, 2005, to December 31, 2018, the cohort enrollment period. Participants were examined for primary and secondary outcomes that occurred within 20 years of their cohort entry date. Individuals were required to have at least one healthcare visit within 2 years of their cohort entry. Patients were excluded if they had any diagnosis of dementia, mild cognitive impairment, or amnesia at any time before cohort entry (Tables S2–S3). Study outcomes The primary outcome was all‐cause dementia, based on International Classification of Diseases, Tenth Revision (ICD‐10) codes F01, F02, F03, G30, G31.0, or G31.83 within 20 years of enrollment. In additional analyses, we investigated mild cognitive impairment (ICD10: G31.84) and memory loss as a proxy for retrograde and other forms of amnesia (ICD10: R41.2, R41.3) (Table S3). Covariates We measured potential confounders up to 20 years prior to the cohort entry date. The following variables were included in propensity score matching: age, sex, race, ischemic heart diseases, cerebrovascular diseases, chronic kidney disease, acute kidney failure, venous embolism and thrombosis, nicotine dependency, alcohol dependence, history of healed traumatic brain injury, vision loss, sleep disorders, dietary counseling, physical activity, and neoplasms, antilipemic agents, beta blockers, calcium channel blockers, antiarrhythmics, diuretics, angiotensin‐converting enzyme inhibitors, angiotensin II inhibitors, insulin, oral hypoglycemic agents, and other hypoglycemic agents. The confounders included were identified using ICD‐10 diagnoses and generic drug names (Veterans Affairs Drug Classification system) (Table S4). Statistical analysis We compared baseline characteristics between groups using chi‐square tests for categorical variables and independent t‐tests for continuous variables. We used 1:1 propensity score matching with logistic regression, using greedy nearest‐neighbor matching with a tolerance level of 0.01 and a maximum allowable difference of 0.1 between propensity scores. To estimate the probability of each outcome over time, we conducted Kaplan–Meier survival analyses. Patients were censored the day after their last recorded medical visit or outcome event. Hazard ratios (HRs), risk differences (RDs), and 95%CIs were used to describe the risk of the outcomes by comparing time‐to‐event rates. The proportional hazards assumption was tested using the generalized Schoenfeld method. Data were collected and analyzed on August 16, 2025, within the TriNetX Analytics platform. RESULTS Characteristics of the study population The final cohort after propensity score matching comprised 4106 participants with cochlear implants and 4106 participants with hearing loss without cochlear implants (Figure 1, Table 1). TABLE 1Baseline characteristics of participants with cochlear implants and matched controls with untreated hearing loss after 1:1 propensity score matching.Cochlear device implants cohort versus untreated hearing loss (control) cohortCochlear implantsControls with untreated hearing lossStandardized mean difference Total, n 41064106Age, mean ± SD66.6 ± 8.766.5 ± 8.70.007 Sex (%) Female1949 (47.5)1964 (47.8)0.007Male2157 (52.5)2142 (52.2)0.007 Ethnicity (%) Hispanic/Latinx159 (3.9)146 (3.6)0.017Not Hispanic/Latinx3456 (84.2)3447 (84.0)0.006Unknown491 (12.0)513 (12.5)0.016 Race (%) Asian82 (2.0)96 (2.3)0.023Black210 (5.1)200 (4.9)0.011White3420 (83.3)3476 (84.7)0.037Other100 (2.4)87 (2.1)0.021 Cardiovascular and other risks/conditions (%) Hyperlipidemia719 (17.5)766 (18.7)0.030Type 2 diabetes523 (12.7)509 (12.4)0.010Overweight and obesity339 (8.3)353 (8.6)0.012Ischemic heart diseases430 (10.5)459 (11.2)0.023Cerebrovascular diseases246 (6.0)240 (5.8)0.006Other venous embolism and thrombosis61 (1.5)43 (1.0)0.039Chronic kidney disease172 (4.2)161 (3.9)0.014Acute kidney failure70 (1.7)83 (2.0)0.023Depressive episode326 (7.9)296 (7.2)0.028Nicotine dependence178 (4.3)207 (5.0)0.033Alcohol‐related disorders58 (1.4)58 (1.4)<0.001Neoplasms759 (18.5)744 (18.1)0.009Unspecified vision loss28 (0.7)36 (0.9)0.022Sleep disorders449 (10.9)429 (10.4)0.016Dietary counseling and surveillance19 (0.5)16 (0.4)0.011Activity codes10 (0.2)16 (0.4)0.026 Medications (%) Insulin262 (6.4)247 (6.0)0.015Oral hypoglycemic agents440 (10.7)448 (10.9)0.006Other oral hypoglycemic agents26 (0.6)19 (0.5)0.023Antilipemic agents1447 (35.2)1504 (36.6)0.029Beta blockers870 (21.2)907 (22.1)0.022Calcium channel blockers579 (14.1)640 (15.6)0.042Antiarrhythmics664 (16.2)676 (16.5)0.008Diuretics1044 (25.4)1118 (27.2)0.041Angiotensin‐converting enzyme inhibitors767 (18.7)818 (19.9)0.031Angiotensin II inhibitors465 (11.3)503 (12.3)0.029 Note: Data are n (%) unless stated otherwise. Baseline characteristics of participants with cochlear implants and matched controls with untreated hearing loss after 1:1 propensity score matching. Note: Data are n (%) unless stated otherwise. Cochlear implants and risk for all‐cause dementia A total of 404 cases of dementia, 226 cases of mild cognitive impairment, and 508 cases of memory loss were identified during a median 7.3‐year follow‐up: 146 among participants who underwent cochlear implantation (incidence rate [IR] 5.0, 95% CI 4.19–5.81; mean follow‐up time: 2599 days), 258 among participants with hearing loss who did not undergo cochlear implantation (IR 8.36, 95% CI 7.34–9.38 per 1000 person‐years; mean follow‐up time: 2746 days). Dementia subtypes and their HRs are available in Figure S1. Full characteristics are summarized in Table 1, and all covariates had a standardized mean difference <0.1 after matching. Participants who underwent cochlear implantation had a lower HR for all‐cause dementia (HR 0.61, 95% CI 0.50–0.74; RD –3.26, 95% CI −4.55 to −1.97), mild cognitive impairment (HR 0.53, 95% CI 0.40–0.70; RD −2.27, 95% CI −3.23 to −1.30), and memory loss (HR 0.54, 95% CI 0.45–0.65; RD −4.87, 95% CI −6.31 to −3.42) than participants with hearing loss who did not undergo the procedure. These associations remained significant in both male and female participants (Figure 2A–A, Figure S1–S3). Cumulative incidence plots using Kaplan–Meier estimates of medical encounters for all‐cause dementia, mild cognitive impairment, and memory loss. DISCUSSION In this large cohort of adults with hearing loss, our findings suggest that cochlear implantation is associated with a significantly reduced risk of all‐cause dementia, mild cognitive impairment, and memory loss. It is well established that hearing loss is a major modifiable risk factor for dementia. 2 Although the mechanisms linking hearing loss to cognitive decline are not fully understood, several hypotheses have been proposed. For instance, in individuals with hearing loss, more cognitive resources are allocated to auditory processing and fewer to executive function, 6 , 7 presumably leading to atrophy in the primary auditory cortex and the right temporal lobe. 8 , 9 These findings raised the question of whether hearing restoration devices could slow the progression of cognitive decline posed by hearing loss. It is postulated that hearing aids may help reduce cognitive decline by mitigating some consequences of hearing loss, such as social isolation, depression, and cognitive load. 10 Although results from randomized clinical trial of hearing aid intervention did not demonstrate improved cognitive performance at a 3‐year follow‐up, 11 evidence remains scarce for longer‐term follow‐up periods. A recent meta‐analysis found that individuals who used hearing aids displayed a lower risk of developing dementia compared to controls with untreated hearing loss (HR 0.81; 95% CI 0.76–0.87; I2 = 0%) and showed improvement in short‐term cognitive tests (ratio of means, 1.03; 95% CI 1.02–1.04, I2 = 0%). 3 A subgroup analysis of nine studies showed mild improvement in cognitive test scores (Mini‐Mental State Examination [MMSE], Montreal Cognitive Assessment (MoCA], Digit Symbol Substitution Test [DSST]) after cochlear implantation (ratio of means 1.03; 95% CI 1.02–1.05). 3 However, these studies evaluated short‐term cognitive performance, whereas our study investigated long‐term reductions in dementia risk over a longer follow‐up period. Although the mechanism by which hearing loss increases the risk of dementia is not fully elucidated, 12 our findings support the growing consensus that intervening to correct hearing loss 13 may be an effective strategy for dementia prevention. Our study presents limitations. First, given the large‐scale, multicenter nature of this study, some degree of bias and diagnostic inconsistency is expected in ICD codes, which could vary among physicians. Second, the models used did not account for mortality as a competing risk in our cohort, which may have affected the estimated HRs. Finally, patients undergoing cochlear implantation usually have severe to profound hearing loss, which typically does not benefit from hearing aids. Consequently, we could not match the severity of hearing loss in the control group; our estimated HRs may underestimate the real‐world effect of cochlear implants on dementia incidence. Future research is needed to evaluate the influence of cochlear implants on cognitive decline and dementia incidence in diverse ethnic populations. CONCLUSION This cohort study highlights the potential of cochlear implants to mitigate the long‐term risk of cognitive decline. AUTHOR CONTRIBUTIONS F.A. had access to and verified the underlying study data, ensured the integrity and accuracy of the data analysis, and is the guarantor. F.A. drafted the manuscript. All authors contributed to the study design, data analysis and interpretation, and the critical revision of the manuscript. C.D. supervised the study. The corresponding author confirms that all listed authors meet the criteria for authorship and that no other authors meeting the criteria have been excluded. CONFLICT OF INTEREST STATEMENT The authors have no competing interests. Author disclosures are available in the Supporting Information. CONSENT STATEMENT This study used population‐level aggregate and de‐identified data collected by the TriNetX Platform, which are available from TriNetX (https://trinetx.com/); however, third‐party restrictions apply to the availability of these data. These data were used under license for this study, with restrictions that do not allow for the data to be redistributed or made publicly available. To gain access to the data, a request can be made to TriNetX (join@trinetx.com), but costs might be incurred, and a data‐sharing agreement would be necessary. As the data are routinely collected and fully anonymized, patient consent is not required. Data specific to this study, including diagnosis codes and group characteristics in aggregated format, are included in the paper as tables, figures, and supplementary online content. Supporting information Supporting information: dad270409‐sup‐0001‐ICMJE.pdf Supporting information: dad270409‐sup‐0002‐SuppMat.docx